Chemicon International and Cellumen Announce an R & D Agreement to Commercialize a Systems Cell Biology Approach to Cytotoxicity

Serologicals Corporation (NASDAQ: SERO) announced today
that Chemicon International, Inc., its wholly-owned subsidiary, has
entered into a research and development agreement with Cellumen, Inc.,
to commercialize a cytotoxicity profiling panel and services designed
with Chemicon and Upstate's market-leading cellular assay reagents and
Cellumen's system cell biology approach. Chemicon will focus on the
development and production of the resulting assays and panels, while
Cellumen will focus on their use in profiling services and knowledge
generation. The companies will jointly market these solutions to the
pharmaceutical industry.
   "We are pleased to combine our expertise in reagent technologies
with the systems cell biology approach being pioneered by Cellumen,"
stated Jeffrey D. Linton, President of Chemicon and Upstate, which
comprise Serologicals' Research Segment. "The use of cellular systems
to profile toxic responses at the earliest stages in drug development
will enhance the ability of our Pharmaceutical customers to select
appropriate compounds for further development and represents a major
opportunity to address the attrition rate in the process. We are
committed to bringing the highest quality reagents and services to the
life sciences market to address the major challenges in basic
research, and drug development."
   "Systems cell biology is the study of the cell as the basic unit
of life: an integrated and interacting network of genes, proteins and
biochemical reactions which give rise to functions and life," stated
D. Lansing Taylor, Ph. D., CEO of Cellumen, Inc. "Cytotoxicity must be
viewed as a systems response and not just the response of a few
cellular constituents. There is great potential to have a systems cell
biology profile that will be predictive of the human toxic response.
This is a major challenge in the drug development process."

   Chemicon International, Inc. offers a broad range of research
products, including specialty reagents, kits, antibodies, and custom
products and services, to customers working in the areas of
neuroscience, stem cell biology, cancer, and infectious disease
research. It is also a leading supplier of monoclonal antibodies,
conjugates, antibody blends and molecular-based detection kits for use
in diagnostic laboratories. Chemicon focuses on basic and biomedical
research, drug discovery, and diagnostics, allowing it to serve
thousands of customers worldwide in the academic, clinical,
biotechnology, and pharmaceutical sectors. Acquired in 2003, Chemicon
is a Serologicals company, based in Temecula, CA.
   For more information, please visit our website: www.chemicon.com

   Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta,
GA, is a global leader in developing and commercializing consumable
biological products, enabling technologies and services in support of
biological research, drug discovery, and the bioprocessing of
life-enhancing products. Our customers include researchers at major
life science companies and leading research institutions involved in
key disciplines, such as neurology, oncology, hematology, immunology,
cardiology, proteomics, infectious diseases, cell signaling and stem
cell research. In addition, Serologicals is the world's leading
provider of monoclonal antibodies for the blood typing industry.
Serologicals employs a total of more than 1,000 people worldwide in
three Serologicals' companies: Chemicon International, headquartered
in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville,
VA, and Celliance Corporation, headquartered in Atlanta, GA.
   For more information, please visit our website:
www.serologicals.com

   About Cellumen Inc.: Cellumen is a systems cell biology company
that performs collaborative discovery programs with pharmaceutical,
biotechnology and personalized medicine companies. Powerful cellular
models of disease and integrated function are created using
proprietary reagents that measure and manipulate cellular
constituents. The systems cell biology approach integrates high
throughput and high content analyses with proprietary informatics
tools to create a profile of systemic function and dysfunction.
   For more information, please visit www.cellumen.com

   This release contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995.
Words or phrases such as "should result," "are expected to," "we
anticipate," "we estimate," "we project" or similar expressions are
intended to identify forward-looking statements. These statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those expressed in any
forward-looking statements. You should not place undue reliance on
forward-looking statements, since the statements speak only as of the
date that they are made, and the Company undertakes no obligation to
update these statements based on events that may occur after the date
of this press release.
   Serologicals is a registered trademark of Serologicals Royalty
Company.